Expanded Access CELZ-201-DDT

Creative Medical Technology Holdings, Inc. (CMTH) is committed to ensuring ethical, timely, and regulatory-compliant access to its investigational cell therapy, CELZ-201-DDT, for patients with serious or immediately life-threatening conditions who have no comparable or satisfactory alternative treatment options and are unable to participate in ongoing clinical studies. This Expanded Access Policy describes the criteria and process for physicians to request investigational access outside of clinical trials, in line with FDA requirements (21 CFR 312 Subpart I – Expanded Access to Investigational Drugs for Treatment Use).​